After re-examination, the CHMP confirmed its negative opinion of Yartemlea for HSCT-associated TMA, citing insufficient ...
Anti-CD36 alloimmunization may contribute to severe platelet transfusion refractoriness despite negative human leukocyte ...
Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis ...
ABP News on MSN
US FDA approves new hepatitis B treatment: Can patients finally stop taking antivirals?
The US Food and Drug Administration (FDA) has approved a new treatment for adults with chronic hepatitis B, offering some ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
FDA approves GSK and Ionis’ hepatitis B drug Hibsago early, but a boxed warning and weekly lab monitoring could slow uptake.
Health and Me on MSN
US FDA approves first-of-its-kind hepatitis B drug that helped 19% patients stay off treatment for six months
The US FDA recently approved Hibsago (bepirovirsen), a new drug for chronic hepatitis B that could help control viral ...
The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
Dr. Norah Terrault, Chief of Gastroenterology & Hepatology, USC Keck Medical Center, said: “This is the start of a new era in treating people living with CHB. Bepirovirsen offers patients the ...
A retrospective series of 11 patients with liver failure found low-dose regional citrate combined with nafamostat feasible ...
The United States has approved a new treatment for chronic hepatitis B that could allow some patients to stop taking antiviral medicines while maintaining control over the virus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results